COVID-19 and Rheumatology

COVID-19 Impact: The Journal team is working extremely hard during this extraordinary time. We continue to adapt our business practices to COVID-19 developments and ensure delivery of our products and services. Subscribers can notify our Subscriptions Department of address changes to continue receiving our monthly print and online editions.

As well as continuing to receive submissions in rheumatology, we are also accepting submissions on COVID-19, and we are reviewing and preparing them for publication as soon as possible. You can access all articles here.

We are monitoring developments closely and will adhere to policies set forth by our health authorities. We will always give updates about any changes that will affect you, our valued customers and subscribers.

We promise to serve our community as best we can through this uncertain time, and we thank you for your continued support.

Stay safe!

Articles

The Rheumatologist's Role in COVID-19
Randy Q. Cron and W. Winn Chatham
The Journal of Rheumatology March 24 2020, jrheum.200334; DOI: https://doi.org/10.3899/jrheum.200334

  • The novel coronavirus (severe acute respiratory syndrome; SARS-CoV-2) pandemic has spread rapidly throughout the planet. It is believed to have originated in the Wuhan province of China, but this highly contagious respiratory virus has spread to over 140 countries on 6 continents as of mid-March 2020, according to the World Health Organization. Worldwide, there have been over 164,000 cases identified and over 6500 deaths attributed to the viral infection...

Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic
Rosie Scuccimarri, Evelyn Sutton and Mary-Ann Fitzcharles
The Journal of Rheumatology April 2 2020, jrheum.200369; DOI: https://doi.org/10.3899/jrheum.200369

  • Two antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ), have been trusted treatments for a range of rheumatic diseases over the past seventy years [1]. These agents have attracted intense media attention in the past few weeks with suggestions that this category of drugs may have potential in the management of coronavirus (SARS-CoV2) associated disease called COVID-19...

Calling All Rheumatologists!
Vaneet Sandhu
The Journal of Rheumatology April 7 2020, jrheum.200421; DOI: https://doi.org/10.3899/jrheum.200421

  • These are difficult times. First responders are putting their lives at risk in order to save others'. But this is our profession; we chose to work in the healthcare industry, knowing our daily exposures to different people with diverse ailments. Nobody chose this profession thinking they would one day be part of a pandemic, fearing for their lives and those of their loved ones by proxy.

Learning from Adversity: Lessons from the COVID-19 Crisis
Michael S. Putman and Eric M. Ruderman
The Journal of Rheumatology April 8 2020, jrheum.200411; DOI: https://doi.org/10.3899/jrheum.200411

  • One month into the COVID-19 crisis in the US, rheumatologists have begun to feel the effects of our hastily constructed temporary response plans. While we may not be staffing the front lines with our colleagues in emergency medicine and critical care, our patients are uniquely vulnerable to infection and continue to require care...

Possible Consequences of a Shortage of Hydroxychloroquine for Lupus Patients Amid the COVID-19 Pandemic
Christine A. Peschken
The Journal of Rheumatology April 8 2020, jrheum.200395; DOI: https://doi.org/10.3899/jrheum.200395

  • As the COVID-19 pandemic took hold in North America, rheumatology clinics across the continent were inundated with phone calls from lupus patients understandably fearful of COVID-19. One of the most common questions from patients was whether they should stop taking their lupus medications...

The Plight of Patients with Lupus Nephritis in Wuhan, China
Cheng Chen, Biqing Yao, Miao Yan, Ke Su, Huiming Wang and Chuanhui Xu
The Journal of Rheumatology May 2020, jrheum.200452; DOI: https://doi.org/10.3899/jrheum.200452

  • The number of cases of SARS-CoV2 infection is rising rapidly globally. Severe disease and high fatality are observed in older patients and with comorbid conditions (1)...

Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials
Stephen J. Balevic, Christoph P. Hornik, Thomas P. Green, Megan E.B. Clowse, Daniel Gonzalez, Anil R. Maharaj, Laura E. Schanberg, Amanda M. Eudy, Geeta K. Swamy, Brenna L. Hughes and Michael Cohen-Wolkowiez
The Journal of Rheumatology May 2020, jrheum.200493; DOI: https://doi.org/10.3899/jrheum.200493

  • Objective: To characterize hydroxychloroquine exposure in patients with rheumatic disease receiving long-term hydroxychloroquine compared to target concentrations with reported antiviral activity against the 2019 coronavirus SARS-CoV-2.

COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?
Hannah Jethwa, Ann Sullivan and Sonya Abraham
The Journal of Rheumatology May 2020, jrheum.200527; DOI: https://doi.org/10.3899/jrheum.200527

  • The implications of COVID-19 are wide-ranging for specialties, like Rheumatology, where immunomodulatory therapies are prescribed, and there has been much trepidation amongst many healthcare professionals regarding the best course of management during this time. This pandemic has also left many national policy-makers perplexed due to our limited knowledge of the effects of COVID-19 in patients with rheumatic disease. Such limitations have resulted in variable evolving guidance amongst Rheumatologists around the globe.

Correspondence

Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs
Giovanni Filocamo, Francesca Minoia, Simone Carbogno, Stefania Costi, Micol Romano and Rolando Cimaz for the Pediatric Rheumatology Group of the Milan Area
The Journal of Rheumatology April 2020, jrheum.200483; DOI: https://doi.org/10.3899/jrheum.200483

The Question of Whether to Remain on Therapy for Chronic Rheumatic Diseases in the Setting of the Covid-19 Pandemic
Randy Q. Cron and W. Winn Chatham
The Journal of Rheumatology April 2020, jrheum.200492; DOI: https://doi.org/10.3899/jrheum.200492

Evidence of Protective Effect of Hydroxychloroquine to Prevent COVID-19
Beuy Joob and Viroj Wiwanitkit
The Journal of Rheumatology May 2020, jrheum.200638; DOI: https://doi.org/10.3899/jrheum.200638

Dr. Balevic, et al, reply
Stephen J. Balevic, Christoph P. Hornik, Thomas P. Green, Megan E.B. Clowse, Daniel Gonzalez, Anil R. Maharaj, Laura E. Schanberg, Amanda M. Eudy, Geeta K. Swamy, Brenna L. Hughes and Michael Cohen-Wolkowiez
The Journal of Rheumatology May 2020, jrheum.200681; DOI: https://doi.org/10.3899/jrheum.200681

SARS-CoV-2: Viral Mechanisms and Possible Therapeutic Targets – What to learn from Rheumatologists?
Carlos Antonio Mouraa and Ana Luísa Cerqueira de Sant’Ana Costa
The Journal of Rheumatology May 2020, jrheum.200657; DOI: https://doi.org/10.3899/jrheum.200657

Treating Covid-19 at the Inflection Point
W. Winn Chatham and Randy Q. Cron
The Journal of Rheumatology May 2020, jrheum.200679; DOI: https://doi.org/10.3899/jrheum.200679

No SLE with COVID-19 in Hong Kong: The Effect of Masking?
Ho So, Joyce Wing Yan Mak and Lai-shan Tam
The Journal of Rheumatology June 2020, jrheum.200605; DOI: https://doi.org/10.3899/jrheum.200605

Are Patients with Systemic Lupus Erythematosus at Increased Risk of Severe COVID-19?
Ennio Giulio Favalli, Elena Agape and Roberto Caporali
The Journal of Rheumatology June 2020, jrheum.200723; DOI: https://doi.org/10.3899/jrheum.200723

Rheumatologists and Pulmonologists at Temple University Weather the COVID-19 Storm Together
Roberto Caricchio and Gerard J. Criner
The Journal of Rheumatology June 2020, jrheum.200740; DOI: https://doi.org/10.3899/jrheum.200740

Teamwork, A Novel Concept During an Infectious Pandemic?
Randy Q. Cron and W. Winn Chatham
The Journal of Rheumatology June 2020, jrheum.200744; DOI: https://doi.org/10.3899/jrheum.200744

Contents

Author Interviews & Videos

Rheumatologists and Pulmonologists at Temple University Weather the COVID-19 Storm Together
Roberto Caricchio and Gerard J. Criner

  • Editor-in-Chief Dr. Earl Silverman speaks with Dr. Roberto Caricchio from Lewis Katz School of Medicine, Temple University about his and his co-author's letter Rheumatologists and Pulmonologists at Temple University Weather the COVID-19 Storm Together.

The Plight of Patients with Lupus Nephritis in Wuhan, China
Cheng Chen, Biqing Yao, Miao Yan, Ke Su, Huiming Wang and Chuanhui Xu

  • Editor-in-Chief Dr. Earl Silverman speaks with Dr. Chuanhui Xu from Tan Tock Seng Hospital about his and his co-authors' letter The Plight of Patients with Lupus Nephritis in Wuhan, China. [Read the full transcript.]

Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials
Stephen J. Balevic, Christoph P. Hornik, Thomas P. Green, Megan E.B. Clowse, Daniel Gonzalez, Anil R. Maharaj, Laura E. Schanberg, Amanda M. Eudy, Geeta K. Swamy, Brenna L. Hughes and Michael Cohen-Wolkowiez

  • Dr. Stephen J. Balevic from Duke University School of Medicine presents their findings. [Read the author notes.]

Learning from Adversity: Lessons from the COVID-19 Crisis
Michael S. Putman and Eric M. Ruderman

  • Editor-in-Chief Dr. Earl Silverman speaks with Drs. Michael S. Putman and Eric M. Ruderman from Northwestern University Feinberg School of Medicine about their editorial Learning from Adversity: Lessons from the COVID-19 Crisis. [Read the full transcript.]

Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic
Rosie Scuccimarri, Evelyn Sutton and Mary-Ann Fitzcharles

  • Editor-in-Chief Dr. Earl Silverman speaks with Drs. Rosie Scuccimarri from McGill University, Evelyn Sutton from Dalhousie University, and Mary-Ann Fitzcharles from McGill University about their editorial Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic. [Read the full transcript.]

Possible Consequences of a Shortage of Hydroxychloroquine for Lupus Patients Amid the COVID-19 Pandemic
Christine A. Peschken

  • Editor-in-Chief Dr. Earl Silverman speaks with Dr. Christine A. Peschken from the University of Manitoba about her editorial Possible Consequences of a Shortage of Hydroxychloroquine for Lupus Patients Amid the COVID-19 Pandemic. [Read the full transcript.]

The Rheumatologist's Role in COVID-19
Randy Q. Cron and W. Winn Chatham

  • Editor-in-Chief Dr. Earl Silverman speaks with Drs. Randy Cron and Winn Chatham from the University of Alabama at Birmingham about their article The Rheumatologist's Role in COVID-19 and screening for cytokine storm syndrome among COVID-19 patients. [Read the full transcript.]